Suppr超能文献

接受阿片类激动剂治疗的阿片类物质使用障碍患者中精神障碍与治疗留存率之间的关联:一项系统评价与荟萃分析。

The association between mental disorders and treatment retention among people with opioid use disorder receiving opioid agonist treatment: A systematic review and meta-analysis.

作者信息

Tran Lucy T, McKetin Rebecca, Clark Brodie, Macdonald Christel, Zahra Emma, Arunogiri Shalini, Montebello Mark E, Degenhardt Louisa

机构信息

National Drug and Alcohol Research Centre, UNSW Sydney, Australia.

National Drug and Alcohol Research Centre, UNSW Sydney, Australia.

出版信息

Drug Alcohol Depend. 2025 Sep 1;274:112768. doi: 10.1016/j.drugalcdep.2025.112768. Epub 2025 Jun 24.

Abstract

BACKGROUND

Mental disorders are common among people with opioid use disorder. This review synthesised evidence of the association of comorbid mental disorders on retention with buprenorphine and methadone treatment.

METHODS

A systematic search of PubMed, Embase and PsycInfo was conducted in 2025, using search terms related to opioid use disorder and opioid agonist treatment medications of buprenorphine or methadone. Included studies reported on adults aged ≥ 18 years with opioid use disorder in any treatment setting, measured mental disorders or symptoms of mental disorders and retention in buprenorphine or methadone. Any retention data by mental disorders or symptoms of mental disorders were extracted for analysis.

RESULTS

Of 16,056 papers screened, 48 cohorts were included for analyses, consisting of 151,570 individuals. Our meta-analyses indicated that people with mood or personality disorders are more likely to drop out of buprenorphine treatment at 12 and 24 months, compared to people without these specific disorders. At 24 months, people with depression, bipolar disorder, post-traumatic stress disorder, panic disorder and attention-deficit/hyperactivity disorder are more likely to have ceased buprenorphine treatment, compared to people with no mental disorder. People with psychotic and personality disorders were more likely to be retained in methadone treatment at 24 months compared to either people without these specific disorders or with no mental disorders.

CONCLUSIONS

Among people who have opioid use disorder, mental disorders are associated with poorer retention in buprenorphine treatment from 6 months. The small number of cohorts within each analysis emphasises a further need for studies examining the association between mental disorders and buprenorphine or methadone retention. This review highlights the importance of clinicians in assessing for comorbid mental disorders to facilitate appropriate long-term care and improve treatment outcomes.

摘要

背景

精神障碍在阿片类物质使用障碍患者中很常见。本综述综合了共病精神障碍与丁丙诺啡和美沙酮治疗留存率之间关联的证据。

方法

2025年对PubMed、Embase和PsycInfo进行了系统检索,使用了与阿片类物质使用障碍以及丁丙诺啡或美沙酮等阿片类激动剂治疗药物相关的检索词。纳入的研究报告了在任何治疗环境中年龄≥18岁的阿片类物质使用障碍成年人,测量了精神障碍或精神障碍症状以及丁丙诺啡或美沙酮治疗的留存率。提取了按精神障碍或精神障碍症状分类的任何留存数据进行分析。

结果

在筛选的16056篇论文中,纳入了48个队列进行分析,共151570人。我们的荟萃分析表明,与没有这些特定障碍的人相比,患有情绪或人格障碍的人在12个月和24个月时更有可能退出丁丙诺啡治疗。在24个月时,与没有精神障碍的人相比,患有抑郁症、双相情感障碍、创伤后应激障碍、惊恐障碍和注意力缺陷多动障碍的人更有可能停止丁丙诺啡治疗。与没有这些特定障碍或没有精神障碍的人相比,患有精神病性障碍和人格障碍的人在24个月时更有可能继续接受美沙酮治疗。

结论

在患有阿片类物质使用障碍的人群中,精神障碍与6个月后丁丙诺啡治疗的留存率较低有关。每次分析中的队列数量较少,这进一步凸显了开展研究以检验精神障碍与丁丙诺啡或美沙酮留存率之间关联的必要性。本综述强调了临床医生在评估共病精神障碍以促进适当的长期护理和改善治疗结果方面的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验